Toll-like receptors 7 and 8 (TLR7 and TLR8) are endosomal immune receptors that initiate an innate immune response and can facilitate activation of the adaptive immune system. Both preclinical and ...

Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 2020

The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker Methods for treating cancer with the immunoconjugates of the invention are also described

Antibody adjuvant conjugates

Imidazoquinoline compounds of formula (IA), conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed imidazoquinoline compounds are useful, among other things, in the treating of cancer and modulating TLR7. Additionally, imidazoquinoline compounds incorporated into a conjugate with an antibody construct are described herein.

Antibody conjugates of toll-like receptor agonists

Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.

Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof

Aqueous formulations comprising conjugates that comprise a compound comprising benzazepine or a benzazepine-like structure conjugated to a polypeptide are provided, as well as methods of treatment using the aqueous formulations. Lyophilized compositions comprising the conjugates that comprise a compound comprising benzazepine or a benzazepine-like structure conjugated to a polypeptide are also provided.

Formulations of Benzazepine Conjugates and Uses Thereof

Various compositions are disclosed for the treatment of viral infections. The compositions comprise antibody constructs directed to the liver, attached to myeloid cell agonists, specifically TLR7 and TLR8 agonists, via a linker. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating viral infections, such as viral liver diseases.

Antibody construct-drug conjugate for the treatment of hepatitis

Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGFβR1, TGFβR2, TNKS, TNIK, or mTOR.

Antibody conjugates of immune-modulatory compounds and uses thereof

Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.

Compositions for the treatment of disease with immune stimulatory conjugates

Anti-mesothelin antibodies and conjugates comprising such antibodies are disclosed herein as well as the use of such conjugates in the treatment of disease, such as cancer.

Odegard Valerie

Papers

Antibody construct-drug conjugate for the treatment of hepatitis

Antibody conjugates of immune-modulatory compounds and uses thereof

Compositions for the treatment of disease with immune stimulatory conjugates

Anti-mesothelin antibodies and immunoconjugates thereof